Who
Barbara Klencke
Director
Company insider
Files Form 4 as: Director, Xencor; Director, TScan Therapeutics; Chief Medical Officer, ALX Oncology Holdings; Director, eFFECTOR Therapeutics; Chief Medical Officer, Sierra Oncology.
In numbers
- Trades disclosed
- 58
- Buys
- 7
- Sells
- 0
- Bought
- $322K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 8 Mar 2016
- Last trade
- 16 Jun 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 17 Sep 2025filed 19 Sep 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —27,372 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —13,686 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 23 Sep 2024filed 24 Sep 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $26K5,000 at $5.29 | filing |
| 26 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K5,000 at $5.53 | filing |
| 23 Aug 2024filed 27 Aug 2024 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K5,000 at $5.69 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —11,971 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —5,986 at $0.00 | filing |
News
Critical Survey: TScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY)TCRX · dailypolitical.com · 22 Oct 2026AbbVie (NYSE:ABBV) & TScan Therapeutics (NASDAQ:TCRX) Financial ComparisonTCRX · tickerreport.com · 22 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyTCRX · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Barbara Klencke; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.